ALBENZA

LOE ApproachingSM

albendazole

NDAORALTABLETPriority Review

Approved

Jun 1996

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Clinical Trials

Mechanism of Action

Cytochrome P450 1A Inducers

Pharmacologic Class:

Anthelmintic

Indications (7)

parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm Taenia solium cystic hydatid disease of the liver lung peritoneum caused by the larval form of the dog tapeworm Echinococcus granulosus

Clinical Trials (5)

NCT07258173Phase 2Not Yet Recruiting

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

Started Jan 2026

100 enrolled

Trichuris InfectionTrichuris

NCT06201559Phase 1Completed

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

Started Aug 2023

70 enrolled

Intestinal Diseases

NCT04913610Phase 2Terminated

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Started May 2021

153 enrolled

Onchocerciasis

NCT01755637Phase 1Completed

Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population

Started Apr 2012

56 enrolled

Helminthiasis

NCT00659997Phase 4Completed

Efficacy Albendazole and Levamisole Against STH on Unguja

Started Jun 2006

20 enrolled